MedTrace Logo

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05271604 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-09-26

No results posted yet for this study

Summary

This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Conditions

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Cancer
  • Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL

Ozuriftamab Vedotin

Conditionally active biologic anti-ROR2 antibody drug conjugate

BIOLOGICAL

Pembrolizumab

PD-1 inhibitor

BIOLOGICAL

Evalstotug (BA3071)

Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody

BIOLOGICAL

Cetuximab

Epidermal growth factor receptor (EGFR) antagonist

Sponsors & Collaborators

  • BioAtla, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-13
Primary Completion
2025-09-22
Completion
2025-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05271604 on ClinicalTrials.gov